Masaaki Matsuura

Summary

Affiliation: Cancer Institute Hospital
Country: Japan

Publications

  1. ncbi request reprint Modeling late entry bias in survival analysis
    Masaaki Matsuura
    Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135 8550, Japan
    Biometrics 61:559-66. 2005
  2. pmc Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3
    Toshiro Migita
    The Cancer Institute, Tokyo, Japan
    Am J Pathol 176:1756-66. 2010
  3. doi request reprint High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy
    Tomo Osako
    Divisions of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:1431-8. 2010
  4. doi request reprint Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations
    Miyako Hiramatsu
    Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research JFCR, 3 8 31 Ariake, Koto ku, Tokyo 135 8550, Japan
    Lung Cancer 70:94-102. 2010
  5. doi request reprint Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:233-41. 2010
  6. pmc Common peak approach using mass spectrometry data sets for predicting the effects of anticancer drugs on breast cancer
    Masaru Ushijima
    Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer Inform 3:285-93. 2007
  7. doi request reprint Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma
    Madoka Morota
    Department of Radiation Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Int J Radiat Oncol Biol Phys 75:122-8. 2009
  8. doi request reprint ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer
    Toshiro Migita
    Divisions of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer Res 68:8547-54. 2008
  9. doi request reprint Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Cancer Chemother Pharmacol 63:865-71. 2009
  10. ncbi request reprint Histological features of breast cancer, highly sensitive to chemotherapy
    Rie Horii
    Department of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, Koto ku, Tokyo, 135 8550, Japan
    Breast Cancer 14:393-400. 2007

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Modeling late entry bias in survival analysis
    Masaaki Matsuura
    Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135 8550, Japan
    Biometrics 61:559-66. 2005
    ..We apply this method to mortality analysis among atomic bomb survivors defined in a geographical study region...
  2. pmc Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3
    Toshiro Migita
    The Cancer Institute, Tokyo, Japan
    Am J Pathol 176:1756-66. 2010
    ..IGFBP-2, therefore, may offer a novel therapeutic target and serve as an antiapoptotic biomarker for lung adenocarcinoma...
  3. doi request reprint High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy
    Tomo Osako
    Divisions of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:1431-8. 2010
    ..To determine the highly sensitive and highly resistant subsets to cytotoxic chemotherapy, we evaluated predictive factors for pCR and PD to NAC, and assessed the similarities in these factors...
  4. doi request reprint Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations
    Miyako Hiramatsu
    Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research JFCR, 3 8 31 Ariake, Koto ku, Tokyo 135 8550, Japan
    Lung Cancer 70:94-102. 2010
    ..The signal proteins were differently related to mutation status from cultured cells...
  5. doi request reprint Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:233-41. 2010
    ....
  6. pmc Common peak approach using mass spectrometry data sets for predicting the effects of anticancer drugs on breast cancer
    Masaru Ushijima
    Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer Inform 3:285-93. 2007
    ..The analysis gives good performance in the sense of test errors for classifying the class labels for a given feature vector of selected peak values...
  7. doi request reprint Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma
    Madoka Morota
    Department of Radiation Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Int J Radiat Oncol Biol Phys 75:122-8. 2009
    ..To evaluate late cardiopulmonary toxicities after concurrent chemoradiotherapy (CCRT) for esophageal carcinomas...
  8. doi request reprint ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer
    Toshiro Migita
    Divisions of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer Res 68:8547-54. 2008
    ..Taken together, these findings suggest that ACLY is involved in lung cancer pathogenesis associated with metabolic abnormality and might offer a novel therapeutic target...
  9. doi request reprint Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Cancer Chemother Pharmacol 63:865-71. 2009
    ....
  10. ncbi request reprint Histological features of breast cancer, highly sensitive to chemotherapy
    Rie Horii
    Department of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, Koto ku, Tokyo, 135 8550, Japan
    Breast Cancer 14:393-400. 2007
    ..To establish tailor-made therapy for breast cancer, we investigated the possibility of predicting chemotherapy sensitive cases based on pre-therapeutic histological features...
  11. ncbi request reprint Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer
    Yoko Oishi
    Department of Molecular Diagnosis, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    J Hum Genet 52:271-9. 2007
    ..We also determined that immunohistostaining for the Stathmin1 gene product is a potential tool for predicting the outcome of breast cancer patients with supraclavicular lymph node metastasis...
  12. doi request reprint Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide
    Tetsuo Mashima
    Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto ku, Tokyo, Japan
    Cancer Sci 100:1556-62. 2009
    ..These results indicate that ACS is an apoptosis suppressor and that ACS inhibition could be a rational strategy to amplify the antitumor effect of etoposide...
  13. ncbi request reprint A large-scale gene expression comparison of microdissected, small-sized endometrial cancers with or without hyperplasia matched to same-patient normal tissue
    Yuko Sugiyama
    Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 9:5589-600. 2003
    ..The purpose of our study is to identify genes involved in carcinogenesis of endometrial cancer, especially those differentially expressed by type I and type II cancers...
  14. doi request reprint Identification of the molecular mechanisms for dedifferentiation at the invasion front of colorectal cancer by a gene expression analysis
    Yoshimasa Oku
    Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 14:7215-22. 2008
    ..The aim of this study is to identify gene expression signatures that accompany dedifferentiation at the cancer invasion front in colorectal cancer...
  15. ncbi request reprint Analysis of cancer mortality among atomic bomb survivors in Hiroshima Prefecture, 1968-1997
    Tamara Zhunussova
    Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3, Kasumi, Minami Ku, Hiroshima, 734 8553, Japan
    Hiroshima J Med Sci 52:1-7. 2003
    ..In particular the sharply increased excess relative risk for female breast cancer shown in 1988-1992 dramatically declined during the period 1993-1997...
  16. doi request reprint Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy
    Naoko Honma
    Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    J Clin Oncol 26:3727-34. 2008
    ..A large and systematic study is needed to address these important issues...
  17. ncbi request reprint Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines
    Shingo Dan
    Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1 37 1 Kami Ikebukuro, Toshima ku, Tokyo 170 8455
    Cancer Sci 94:1074-82. 2003
    ..The present results suggest that AKR1B1 and CTSH may be good markers for prediction of sensitivity to certain drugs and that our panel of 39 cell lines has the potential to identify candidate predictive marker genes...
  18. ncbi request reprint Identifying haplotype block structure using an ancestor-derived model
    Hironori Fujisawa
    The Institute of Statistical Mathematics, Tokyo 106 8569, Japan
    J Hum Genet 52:738-46. 2007
    ..The proposed method was powerful from the viewpoint of hotspot sensitivity and was robust to mutation except at the edge of a sequence...
  19. ncbi request reprint Reassessment of the cancer mortality risk among Hiroshima atomic-bomb survivors using a new dosimetry system, ABS2000D, compared with ABS93D
    Hiroaki Katayama
    Department of Information Technology, Radiation Effects Research Foundation, 5 2 Hijiyama Koen, Minami Ku, Hiroshima 732 0815, Japan
    J Radiat Res 43:53-64. 2002
    ..Therefore, it is indicated that a modification of the neutron-dose estimates would not markedly change the conclusions about the cancer mortality risk...